Table 4.
The adjusted mean eGFR change per year of NOACs and warfarin at 1 year(4A) and 2 years(4B).
| A | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug | n | Baseline | Mean GFR | Coefficient (95 %CI) | p-value | Coefficient (95 %CI)* | p-value | Coefficient (95 %CI)** | p-value |
| GFR | at 1-yr | Adjusted for Baseline | Adjusted for CHA2DS2VASc | ||||||
| Characteristics | |||||||||
| Drug | |||||||||
| NOAC | 390 | 65.75 ± 17.35 | 63.09 ± 17.54 | 3.97 (1.86–6.09) | <0.001 | 3.5 (1.39–5.6) | 0.001 | 3.7 (1.6–5.8) | 0.001 |
| Warfarin | 308 | 67.21 ± 18.77 | 62.22 ± 18.67 | Reference | Reference | Reference | |||
| Drug subgroup | |||||||||
| Dabigatran | 132 | 66.46 ± 16.59 | 63.99 ± 16.05 | 4.42 (1.54–7.3) | 0.003 | 3.96 (1.07–6.86) | 0.007 | 4.38 (1.52–7.24) | 0.003 |
| Rivaroxaban | 191 | 67.44 ± 16.91 | 64.84 ± 17.3 | 4.14 (1.59–6.7) | 0.002 | 3.85 (1.31–6.4) | 0.003 | 3.9 (1.35–6.45) | 0.003 |
| Apixaban | 67 | 59.57 ± 18.87 | 56.34 ± 19.61 | 2.61 (-1.12–6.35) | 0.170 | 1.56 (-2.19–5.31) | 0.415 | 1.77 (-1.97–5.52) | 0.352 |
| Warfarin | 308 | 67.21 ± 18.77 | 62.22 ± 18.67 | Reference | Reference | Reference | |||
| B | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug | n | Baseline | Mean GFR | Coefficient (95%CI) | p-value | Coefficient (95%CI)* | p-value | Coefficient (95%CI)** | p-value |
| GFR | at 2-yr | Adjusted for Baseline | Adjusted for CHADVAS | ||||||
| Characteristics | |||||||||
| Drug | |||||||||
| NOAC | 289 | 66.22 ± 17.33 | 61.59 ± 18.41 | 6.67 (3.94–9.39) | <0.001 | 5.96 (3.23–8.68) | 0.001 | 6.35 (3.64–9.05) | <0.001 |
| Warfarin | 320 | 66.96 ± 18.66 | 58.62 ± 18.58 | Reference | Reference | Reference | |||
| Drug subgroup | |||||||||
| Dabigatran | 124 | 66.49 ± 17.37 | 61.49 ± 18.43 | 6.22 (2.67–9.77) | 0.001 | 5.78 (2.23–9.33) | 0.001 | 6.28 (2.76–9.8) | <0.001 |
| Rivaroxaban | 141 | 67.78 ± 16.89 | 63.86 ± 18.08 | 7.83 (4.44–11.22) | <0.001 | 7.03 (3.66–10.4) | <0.001 | 7.35 (3.96–10.74) | <0.001 |
| Apixaban | 24 | 55.68 ± 16.70 | 48.87 ± 15.34 | 2.14 (-4.97–9.24) | 0.555 | 0.38 (-6.71–7.47) | 0.917 | 0.73 (-6.38–7.83) | 0.841 |
| Warfarin | 320 | 66.96 ± 18.66 | 58.62 ± 18.58 | Reference | Reference | Reference | |||
Multiple linear regression analysis, Significant if p < 0.05 .
Coefficient or β for mean eGFR = ml/min/1.73 m2
NOAC = Non vitaminK Oral anticoagulant, eGFR = Glomerular filtration rate(ml/min/1.73 m2).
*
Adjusted for baseline characteristics which were age, sex, stroke, diabetes, baseline eGFR and baseline creatinine
**
Adjusted for CHA2 DS2 VASc score